Catherine Novack

Q: How accurate are Catherine Novack's stock ratings?

About 34% of Catherine's ratings were profitable over a one-year hold, with an average return of +8.3% per rating, measured by 13Foresight from historical prices.

Q: How is Catherine ranked?

Catherine Novack is ranked #263 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

JonesTrading

Wall Street Analyst

★★★★★

#263

on 13Foresight · ranked by our own returns

34%

Success Rate

+8.3%

Average Return

12 of 35 calls profitable · +63.5% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

🔒 5-year track record is Pro. Showing 1-year — upgrade.

📈 Across the calls we could measure, roughly 34% of Catherine Novack's ratings turned a profit when each position was held for 1 year — averaging +8.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

23 Buy 11 Hold 0 Sell

Catherine's Stock Coverage 22 ratings · 2026-10-06

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
CAPR Capricor Therapeutics	Sep 27, 2026	HOLD	Strong Buy +248.5% avg upside 12 analysts	—	-18.2%	·
DTIL Precision BioSciences	Aug 07, 2026	BUY	Strong Buy +276.0% avg upside 12 analysts	$30.00 375.50% Upside	-15.8%	·
WVE Wave Life Sciences	Aug 07, 2026	BUY	Strong Buy +465.8% avg upside 29 analysts	$30.00 700.09% Upside	-38.5%	·
DARE Daré Bioscience	Jul 31, 2026	HOLD	Strong Buy +1493.8% avg upside 14 analysts	—	-30.1%	·
FEMY Femasys	Jul 31, 2026	HOLD	Strong Buy +3047.2% avg upside 6 analysts	—	-26.6%	·
EQ Equillium	Jul 31, 2026	HOLD	Strong Buy +549.5% avg upside 16 analysts	—	-35.9%	·
PRQR ProQR	Jun 26, 2026	BUY	Strong Buy +554.0% avg upside 19 analysts	$10.00 498.88% Upside	+9.2%	·
SPRB Spruce Biosciences	Jun 08, 2026	BUY	Strong Buy +141.3% avg upside 16 analysts	$135.00 197.15% Upside	-13.2%	·
RZLT Rezolute	Jun 02, 2026	BUY	Strong Buy +159.7% avg upside 14 analysts	$6.00 38.66% Upside	+0.2%	·
IBIO Ibio	May 13, 2026	BUY	Strong Buy +433.1% avg upside 13 analysts	$7.00 525.01% Upside	-27.1%	·
KRRO Korro Bio	May 08, 2026	BUY	Buy +175.0% avg upside 19 analysts	$23.00 130.62% Upside	-19.4%	·
TSE:MDNA Medicenna Therapeutics Corp	Apr 10, 2026	HOLD	Strong Buy +1114.4% avg upside 9 analysts	—	-40.8%	·
RLYB Rallybio	Apr 10, 2026	HOLD	Buy +39.1% avg upside 8 analysts	—	+102.4%	·
PVLA Palvella Therapeutics	Feb 24, 2026	BUY	Strong Buy +28.0% avg upside 27 analysts	$209.00 58.14% Upside	+14.5%	·
LRMR Larimar Therapeutics	Feb 24, 2026	BUY	Strong Buy +523.0% avg upside 22 analysts	$13.00 354.60% Upside	-19.8%	·
SEPN Septerna, Inc.	Dec 23, 2025	BUY	Strong Buy +37.5% avg upside 12 analysts	$43.00 13.64% Upside	+33.6%	·
AARD Aardvark Therapeutics, Inc.	Sep 30, 2025	BUY	Buy +273.7% avg upside 12 analysts	$33.00 532.20% Upside	-60.4%	·
ALDX Aldeyra Therapeutics	Aug 08, 2025	BUY	Strong Buy +1613.7% avg upside 21 analysts	$9.00 874.34% Upside	-70.5%	·
DYN Dyne Therapeutics	Jun 25, 2025	BUY	Buy +141.2% avg upside 31 analysts	$30.00 94.38% Upside	+97.8%	·
CALC CalciMedica	Nov 15, 2024	BUY	Buy +1579.9% avg upside 10 analysts	$15.00 873.99% Upside	-9.9%	·
PPBT Purple Biotech	Jun 03, 2024	BUY	Strong Buy +2079.4% avg upside 4 analysts	$60.00 3746.06% Upside	·	·
GYRE Gyre Therapeutics	Nov 15, 2021	HOLD	Strong Buy +182.0% avg upside 15 analysts	—	+25.3%	·

🔒 17 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Catherine Novack — Frequently Asked Questions

How accurate are Catherine Novack's stock ratings?

Based on the calls 13Foresight could measure, about 34% of Catherine's ratings were profitable over a one-year hold, with an average return of +8.3% per rating, or +63.6% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Catherine ranked on 13Foresight?

Catherine Novack is currently ranked #263 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Catherine cover?

Catherine most recently has ratings on CAPR, DTIL, WVE, DARE, FEMY, EQ, PRQR, SPRB, RZLT, IBIO, KRRO, TSE:MDNA and 10 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Catherine Novack

Rating Distribution

Welcome to 13Foresight!